Tags

Type your tag names separated by a space and hit enter

Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen.
Expert Rev Anticancer Ther. 2002 Dec; 2(6):623-9.ER

Abstract

For the past 25 years, the estrogen antagonist tamoxifen has been considered the 'gold standard' for the treatment of breast cancer, despite certain tolerability issues and the risk of developing resistance. The aromatase inhibitors work by blocking the conversion of androgens to estrogen and were developed for use in patients where ovarian function had ceased (naturally, surgically or pharmacologically). Anastrozole, a third-generation nonsteroidal aromatase inhibitor that is a highly potent and selective inhibitor of the aromatase enzyme, has been shown to be superior to the gold standard tamoxifen for the first-line treatment of postmenopausal women with advanced breast cancer. As second-line therapy, anastrozole has shown superior survival compared with megestrol acetate and is also efficacious as neoadjuvant treatment in postmenopausal women and in combination with goserelin for the treatment of premenopausal women with advanced breast cancer. More recently, the results of the ATAC (anastrozole, tamoxifen, alone or in combination) trial, a large study in 9366 patients, demonstrated that anastrozole was significantly superior to tamoxifen for the treatment of postmenopausal women with early breast cancer, with regards to disease-free survival (p = 0.013) and incidence of contralateral breast cancer (p = 0.007). In addition, anastrozole was shown to be significantly better tolerated than tamoxifen with respect to endometrial cancer (p = 0.02), vaginal bleeding/discharge (p < 0.0001 for both), ischaemic cerebrovascular events (p = 0.0006), thromboembolic events (p = 0.0006) and hot flushes (p < 0.0001), while tamoxifen was associated with significantly less musculoskeletal disorders and fractures than anastrozole (p < 0.0001 for both). This review focuses on both the clinical pharmacology and the clinical data of anastrozole with emphasis on its future applications.

Authors+Show Affiliations

Department of Breast Medical Oncology, Box 424, University of Texas MD Anderson Cancer Center, 1515 Holcolme Blvd, Houston, TX 77030, USA. abuzdar@mdanderson.org

Pub Type(s)

Comparative Study
Journal Article
Review

Language

eng

PubMed ID

12503208

Citation

Buzdar, Aman U.. "Anastrozole (Arimidex) in Clinical Practice Versus the Old 'gold Standard', Tamoxifen." Expert Review of Anticancer Therapy, vol. 2, no. 6, 2002, pp. 623-9.
Buzdar AU. Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen. Expert Rev Anticancer Ther. 2002;2(6):623-9.
Buzdar, A. U. (2002). Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen. Expert Review of Anticancer Therapy, 2(6), 623-9.
Buzdar AU. Anastrozole (Arimidex) in Clinical Practice Versus the Old 'gold Standard', Tamoxifen. Expert Rev Anticancer Ther. 2002;2(6):623-9. PubMed PMID: 12503208.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anastrozole (Arimidex) in clinical practice versus the old 'gold standard', tamoxifen. A1 - Buzdar,Aman U, PY - 2002/12/31/pubmed PY - 2003/5/8/medline PY - 2002/12/31/entrez SP - 623 EP - 9 JF - Expert review of anticancer therapy JO - Expert Rev Anticancer Ther VL - 2 IS - 6 N2 - For the past 25 years, the estrogen antagonist tamoxifen has been considered the 'gold standard' for the treatment of breast cancer, despite certain tolerability issues and the risk of developing resistance. The aromatase inhibitors work by blocking the conversion of androgens to estrogen and were developed for use in patients where ovarian function had ceased (naturally, surgically or pharmacologically). Anastrozole, a third-generation nonsteroidal aromatase inhibitor that is a highly potent and selective inhibitor of the aromatase enzyme, has been shown to be superior to the gold standard tamoxifen for the first-line treatment of postmenopausal women with advanced breast cancer. As second-line therapy, anastrozole has shown superior survival compared with megestrol acetate and is also efficacious as neoadjuvant treatment in postmenopausal women and in combination with goserelin for the treatment of premenopausal women with advanced breast cancer. More recently, the results of the ATAC (anastrozole, tamoxifen, alone or in combination) trial, a large study in 9366 patients, demonstrated that anastrozole was significantly superior to tamoxifen for the treatment of postmenopausal women with early breast cancer, with regards to disease-free survival (p = 0.013) and incidence of contralateral breast cancer (p = 0.007). In addition, anastrozole was shown to be significantly better tolerated than tamoxifen with respect to endometrial cancer (p = 0.02), vaginal bleeding/discharge (p < 0.0001 for both), ischaemic cerebrovascular events (p = 0.0006), thromboembolic events (p = 0.0006) and hot flushes (p < 0.0001), while tamoxifen was associated with significantly less musculoskeletal disorders and fractures than anastrozole (p < 0.0001 for both). This review focuses on both the clinical pharmacology and the clinical data of anastrozole with emphasis on its future applications. SN - 1473-7140 UR - https://www.unboundmedicine.com/medline/citation/12503208/Anastrozole__Arimidex__in_clinical_practice_versus_the_old_'gold_standard'_tamoxifen_ DB - PRIME DP - Unbound Medicine ER -